NCT01284387 - Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

February 28, 2014

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL

ACC-001 (vanutide cridificar)

Comparisons of 2 different doses of ACC-001 or placebo for 24 months

Trial Locations (25)

10032

Janssen AI Investigational Site, New York

12205

Janssen AI Investigational Site, Albany

20057

Janssen AI Investigational Site, Washington D.C.

32806

Janssen AI Investigational Site, Orlando

33137

Janssen AI Investigational Site, Miami

33351

Janssen AI Investigational Site, Sunrise

33407

Janssen AI Investigational Site, West Palm Beach

33410

Janssen AI Investigational Site, Miami

33609

Janssen AI Investigational Site, Tampa

33613

Janssen AI Investigational Site, Sun City

33617

Janssen AI Investigational Site, Tampa

34471

Janssen AI Investigational Site, Ocala

45459

Janssen AI Investigational Site, Centerville

64111

Janssen AI Investigational Site, Kansas City

73112

Janssen AI Investigational Site, Oklahoma City

89106

Janssen AI Investigational Site, Las Vegas

90095

Janssen AI Investigational Site, Los Angeles

90806

Janssen AI Investigational Site, Long Beach

92093

Janssen AI Investigational Site, La Jolla

92103

Janssen AI Investigational Site, San Diego

93030

Janssen AI Investigational Site, Oxnard

94143

Janssen AI Investigational Site, San Francisco

04074

Janssen AI Investigational Site, Scarborough

02115

Janssen AI Investigational Site, Boston

08540

Janssen AI Investigational Site, Princeton